Antigen-Dependent and Antigen-Independent Pathways Modulate CD4 ؉ CD28 null T-Cells During Atherosclerosis
To the Editor:
We read with interest the article by Dumitriu et al 1 that characterized the alternative costimulatory pathways of CD4 ϩ CD28 null T cells, a terminally differentiated effector T-cell population, in patients with acute coronary syndromes (ACS). In this study, a significant increase in costimulatory receptors (OX40/CD134 and 4 -1IBB/CD137) was described in CD4 ϩ CD28 null T cells from patients with ACS after stimulation with an anti-CD3 antibody (emulating T-cell antigen recognition). Furthermore, blocking of these costimulatory receptors was associated with reduced interferon-␥, tumor necrosis factor-␣, and perforin release in CD4 ϩ CD28 null T cells, thus affecting their proinflammatory and cytotoxic functions. Overall, these findings suggest a differential sensitivity to costimulation in activated CD4 ϩ CD28 null T cells in the context of ACS.
During ACS we recently observed that in addition to CD28 activation, the classical immunologic synapse mediated by antigen-T-cell receptor (TCR) engagement is perturbed also. 2 Of the TCR subunits, the zeta () chain (CD247 or CD3) has a key role in receptor assembly and antigen recognition by coupling the engaged TCR-CD3 complex to downstream intracellular signal transduction pathways through phosphorylation and intracellular protein recruitment. Downregulation of the TCR chain generally occurs after antigen engagement or in response to inflammatory stimuli as a feedback mechanism aimed at tuning the immune response. Together with CD28 downregulation, TCRchain reduction was observed in T cells isolated in several chronic pathologies, including cancer, and autoimmune (ie, systemic lupus erythematosus) and infectious diseases. 3 Downregulation of TCR-chain expression and impairment of T-cell function, such as loss of TCR-chain expression, defines a population of effector T cells (TCRdim T cells) that migrate to inflamed tissues. 4 We have shown that the TCRdim T-cell subset, although refractory to TCR-induced proliferation, paradoxically displays features of antigen-experienced effector T cells, produces elevated levels of interferon-␥ and tumor necrosis factor-␣, and has a prevalence of memory CD45RO ϩ cells. 4 We further demonstrated that antigen-experienced effector memory T cells (CD3 ϩ CD4 ϩ CD45RO ϩ CCR7 Ϫ ), 5 but not regulatory T cells (CD3ϩCD4ϩCD25 high CD127 low ), 6 are associated with the extent of atherosclerosis and symptomatic coronary artery disease in humans.
In the latter setting, we observed a significant increase in TCRdim T cells and, more importantly, a highly correlation with CD4 ϩ CD28 null T cells (rϭ0.62; Pϭ0.002). 2 Furthermore, a majority of CD4 ϩ CD28 null T cells in ACS (Ͼ65%) were TCRdim T cells compared with chronic stable angina patients (approximately 30%) and controls (approximately 20%). 2 This indicates a potential correlation, in the context of ACS, between impairment in the TCR pathway (signal 1) and in the costimulatory CD28 pathway (signal 2). Given that intact TCR signaling is critical to maintain immune homeostasis through the genera-tion or function of regulatory T-cell subsets, alterations in signal 1 pathway could result in increased TCRdim T cells, which in turn could dampen modulator feedback signals, thus potentially limiting CD4 ϩ CD28 null T-cell responsiveness to inhibitory signals.
However, CD4 ϩ CD28 null T cells can respond to stimuli independent of antigen-mediated TCR pathway. Circulating or plaque CD4 ϩ CD28 null T cells from ACS patients express interleukin-12 receptors, even in the absence of antigenic stimulation, and upregulate the expression of the chemokine receptor CCR5 and the C-type lectin receptor CD161, both implicated in regulating tissue homing of effector T cells after interleukin-12 stimulation. 7 This suggests that CD4 ϩ CD28 null T cells functionally could also resemble natural killer cells, with proinflammatory activity even in the unprimed state and increased tissue trafficking and homing after interleukin-12-inducing host infection associated with accrual in inflammatory lesions.
Both antigen-dependent and antigen-independent mechanisms therefore are critical to elicit response in CD28 and/or TCRchain defective memory T-cell subsets, thus promoting a proinflammatory and proatherosclerotic response. Therefore, a further step in the characterization of CD4 ϩ CD28 null T cells in the context of cardiovascular disorders should be the investigation of their antigen-dependent-mediated and antigen-independent-mediated responses (in terms of costimulatory activities and of TCR-chain impairment), with the aim of defining potential therapeutic targets to inhibit their proinflammatory and proatherosclerotic activities.
